| Year | 2023 | 2022 |
|---|---|---|
| Total Revenue | 21.93B | 24.25B |
| Cost of Revenue | 7.95B | 8.74B |
| Gross Profit | 13.98B | 15.51B |
| Operating Expenses | 4.34B | 8.48B |
| Research and Development | 0 | 0 |
| Selling, General & Administrative Expenses | 4.34B | 3.26B |
| Selling & Marketing Expenses | 1.59B | 615.9M |
| General & Administrative Expenses | 1.04B | 2.65B |
| Other Expenses | 0 | 8.48B |
| Operating Income | 9.61B | 8.04B |
| Total Other Income/Expenses Net | -2.15B | -3.29B |
| Income Before Tax | 7.46B | 8.24B |
| Income Tax | 1.95B | 2B |
| Net Income | 5.51B | 6.24B |
| Basic EPS | 120.51 | 136.38 |
| EPS Diluted | 120.51 | 136.38 |
| Basic Average Shares | 45.75M | 45.75M |
| Diluted Average Shares | 45.75M | 45.75M |
| EBITDA | 8.19B | 9.42B |
Pfizer Limited
PFIZER.NS
NSE
4080.25INR45.35 (1.12%)
PFIZER.NS Financial Statements
Retained Earning Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Retained Earnings (Previous Year) | 14.6B | 11.33B |
| Net Income | 5.51B | 6.24B |
| Stock Repurchases | 0 | 0 |
| Dividend Paid | -1.83B | -2.97B |
| Retained Earnings | 18.28B | 14.6B |
| Other Distributions | 1.85B | 293.7M |
PPE Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Gross PPE | 1.52B | 1.85B |
| Annual Depreciation | 622.8M | 1.04B |
| Capital Expenditure | -189.3M | -649.8M |
| Net PPE | 1.08B | 1.46B |
Intangible and Goodwill Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Acquisitions and Adjustments | 0 | 0 |
| Goodwill (Previous Year) | 5.27B | 5.27B |
| Goodwill | 5.27B | 5.27B |